Recombinant human erythropoietin with advantageous glycosylation profile
AssigneeAventis Pharma Deutschland GmbH
InventorsMathias Fibi, Peter Hermentin
Life of this patent
Estimating the term…
Abstract
A method for the production of a polypeptide, the method comprising culturing, under conditions which allow for the expression of DNA encoding SEQ ID NO:2 in an eukaryotic host cell, wherein the DNA is in vector pPHOEBE-40-7, and optionally isolating the polypeptide from the culture, is described. A polypeptide obtained by such method and a pharmaceutical composition comprising the polypeptide also are described. A composition for diagnosing anemia comprising such polypeptide and a method of treating anemia caused by lack of erythropoietin also are described.
Claims7
A method for the production of a polypeptide, said method comprising culturing, under conditions which allows for the expression of a DNA encoding amino acid sequence SEQ ID NO:2 in an eukaryotic host cell, wherein said DNA is in a vector pPHOEBE-40-7, and optionally isolating said polypeptide from the culture.
An erythropoietin polypeptide produced by expressing DNA encoding amino acid sequence SEQ ID NO:2 in a host cell, wherein said DNA is in the vector pPHOEBE-40-7 and said host cell is a Chinese Hamster Ovary cell, and wherein the erythropoietin polypeptide consists of the amino acid sequence of SEQ ID NO:2.
Dependencies are inferred from the claim text.